Related Experiment Video
Updated: Jul 4, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.
Ambarish Pandey1, Neil Keshvani2,3, Syed K Rizvi2
1Department of Internal Medicine, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX, USA. ambarish.pandey@utsouthwestern.edu.
Nature Medicine
|July 2, 2026
Summary
A polypill strategy significantly improved cardiac function in heart failure patients with reduced ejection fraction. This approach also reduced hospitalizations and improved medication adherence compared to standard care.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Heart failure with reduced ejection fraction (HFrEF) has a poor prognosis.
- Guideline-directed medical therapy (GDMT) improves outcomes but has low real-world utilization.
- Underserved populations often face barriers to optimal HFrEF management.
Purpose of the Study:
- To evaluate the efficacy of a polypill strategy in improving cardiac function in HFrEF patients.
- To compare a polypill approach against enhanced usual care for HFrEF management.
- To assess clinical outcomes, adherence, and safety of the polypill in a diverse population.
Main Methods:
- An open-label, randomized trial (POLY-HF) enrolled 212 adults with HFrEF (ejection fraction ≤40%).
- Participants were randomized to a once-daily polypill (metoprolol succinate, spironolactone, empagliflozin) or enhanced usual care.
- The primary endpoint was ejection fraction improvement at 6 months assessed by cardiac MRI.
Main Results:
- Polypill treatment led to a significantly greater improvement in ejection fraction compared to enhanced usual care (3.3 percentage points, P=0.039).
- Patients on the polypill experienced a 60% lower rate of heart failure hospitalizations or emergency department visits (P=0.024).
- Medication adherence was substantially higher in the polypill group (79% vs. 54%, P=0.001), with good tolerability.
Conclusions:
- A polypill strategy significantly improves cardiac function in HFrEF patients.
- The polypill approach enhances adherence and reduces clinical events in HFrEF.
- Polypills represent a promising strategy for improving HFrEF management, particularly in underserved populations.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...